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AbsTrACT
Objective To determine whether the ratio of 
cerebrospinal fluid (csF) immunoglobulin kappa to 
lambda light chains at time of multiple sclerosis (Ms) 
diagnosis predicts disease progression and whether this 
was intrinsic to csF plasmablasts.
Methods csF and peripheral blood were obtained 
from patients undergoing elective diagnostic lumbar 
puncture and included clinically isolated syndrome (cIs) 
(n=43), relapsing remitting Ms (RRMs; n=50), primary 
progressive Ms (ppMs; n=20) and other neurological 
disease controls, both inflammatory (ONID; n=23) and 
non-inflammatory (OND; n=114). csF samples were 
assayed for free and immunoglobulin-associated light 
chains and on B cells and plasmablasts. clinical follow-
up data were collected during a 5-year follow-up period 
where available.
results There was an increased median csF κ:λ free 
light chain (FLc) in all Ms groups (cIs: 18.2, 95% cI 6.8 
to 30.3; RRMs: 4.4, 95% cI 2.7 to 11.4; ppMs: 12.0, 
95% cI 3.6 to 37.1) but not controls (OND: 1.61, 95% cI 
1.4 to 1.9; ONID: 1.7, 95% cI 1.3 to 2.2; p<0.001). This 
ratio predicted expanded Disability status scores (eDss) 
progression at 5 years, with a lower median eDss in the 
group with high (>10) csF κ:λ FLc (0.0, 95% cI 0 to 2.5 
vs 2.5, 95% cI 0 to 4, high vs low; p=0.049). csF κ:λ 
FLc correlated with csF IgG1 κ:λ (r=0.776; p<0.0001) 
and was intrinsic to csF plasmablasts (r=0.65; p=0.026).
Conclusions These data demonstrate that csF 
immunoglobulin κ:λ ratios, determined at the time 
of diagnostic lumbar puncture, predict Ms disease 
progression and may therefore be useful prognostic 
markers for early therapeutic stratification.
InTrOduCTIOn
Multiple sclerosis (MS) is a chronic inflammatory 
autoimmune disease of the central nervous system, 
usually presenting as a clinically isolated syndrome 
(CIS). Not all patients convert to clinically definite 
MS, and in those who do the level of disability 
accumulation is highly variable.1 Validated long-
term prognostic markers are therefore important 
in guiding the therapeutic choices for individual 
patients. Clinical indicators of poor prognosis 
include a short-time interval between the first two 
relapses, rapid evolution of disease and older age at 
onset.2 3 Baseline MRI lesional topography provides 
some information, and infratentorial lesions and/
or spinal cord lesions have some predictive value 
for disability accumulation.4 5 The best-estab-
lished cerebrospinal fluid (CSF)-based diagnostic 
biomarker are oligoclonal bands (OCB), with a 
potential role in prognostication,6 although this 
observation is not consistent.7 OCB analyses have 
key issues with reproducibility and, as a qualitative 
assay, a limited dynamic range. Other CSF markers 
have been linked to disease progression including 
neurofilament light chains (NFL) and chitinase-3-
like 1 (CHI3L1).8 9 In a manner analogous to OCB, 
we and others have used CSF immunoglobulin (Ig) 
free light chains (FLC) as biomarkers for confirming 
a diagnosis of MS, showing greater sensitivity and 
specificity than OCB.10 There is a general excess 
of κ over λ FLC,10–12 and in one recent study, the 
CSF κ:λ FLC ratio was shown to predict conversion 
from CIS to clinically definite MS (CDMS).13 In this 
study, we have examined the utility of the CSF FLC 
κ:λ ratio as a marker for the development of MS 
disability. 
MeThOds
standard protocol approvals, registrations and 
patient consents
All subjects provided written informed consent, in 
accordance with the Declaration of Helsinki and 
were not on disease-modifying therapies at the time 
of sampling and had not received steroids for at 
least 3 months prior to sampling.
experimental design
Matched peripheral blood and CSF samples were 
prospectively collected during routine diagnostic 
lumbar puncture, and blinding was achieved, with 
all samples analysed before the diagnosis had been 
formally determined. Samples were collected from 
patients with MS fulfilling 2010 revisions of the 
McDonald criteria,14 classified as CIS, relapsing 
remitting MS (RRMS) or primary progressive MS 
(PPMS), as well as patients with other neurological 
diseases (OND) and other neurological inflamma-
tory diseases (ONID) (table 1). Expanded Disability 
Status Scores (EDSS) at 5 years following the diag-
nostic lumbar puncture, annualised relapse rates 
during that period, use of first-line and second-line 
therapy and conversion from CIS to CDMS were 
obtained where available. All diagnostic MRI series 
were further reviewed, with categorisation of infra-
tentorial lesions, according to Minneboo et al.5 
During clinical follow-up, patients were excluded 
where (1) no definitive follow-up data were avail-
able, (2) the CSF samples were OCB negative 
and/or (3) where the FLC values were below the 
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detection limit, not permitting evaluation of an accurate CSF 
FLC κ:λ ratio (online Supplementary figure e1).
Preparation of CsF and peripheral blood
CSF was obtained by non-traumatic lumbar puncture and centri-
fuged (600 g, 8 min). The cell-free CSF was collected and stored 
at −80°C, and CSF cells were stained for flow cytometry (see 
below). Peripheral blood was collected into EDTA-containing 
tubes (Greiner Bio-One, Gloucestershire, UK) and peripheral 
blood mononuclear cells (PBMC) isolated by density gradient 
centrifugation (Ficoll-Paque Plus; GE Healthcare Bioscience).
Flow cytometric analysis
PBMC and CSF cells were analysed as detailed in the online 
Supplementary figure e2.
FLC quantification
FLC concentrations were measured by nephelometry using the 
latex particle-enhanced, Freelite κ and λ immunoassays15 on 
a Dade-Behring BN II Analyser, following the manufacturer’s 
instructions (The Binding Site Group Ltd, Birmingham, UK); 
assays were performed by The Binding Site Group Ltd, using 
anonymised coded samples. Normal serum reference intervals 
were used: κ FLC 3.3–19.4 mg/L and λ FLC 5.7–26.3 mg/L with 
an assay sensitivity of <1 mg/L.16 Normal CSF reference inter-
vals have not been defined. The limit of detection for the κ FLC 
assay was 0.06 mg/L and 0.05 mg/L for the λ FLC assay.
CsF nFL quantification
CSF NFL were measured by ELISA according to the manufac-
turer’s instructions (Uman Diagnostics, Umeå, Sweden). CSF 
samples were diluted 1:1 with sample diluent buffer and concen-
trations calculated from a standard curve.
Table 1 Characteristics of cohorts used for figure 1
disease group Age* Gender (F:M)
  CIS† (n=43) 45.0 (21–70) 2.73:1
  RRMS‡ (n=50) 40.5 (19–72) 3.00:1
  PPMS§ (n=20) 54.5 (35–73) 1.86:1
  OND¶ (n=114) 46.0 (17–85) 2.08:1
  ONID** (n=23) 55.0 (24–83) 0.91:1
*Median (range).
†Clinically isolated syndrome.
‡Relapsing-remitting multiple sclerosis.
§Primary-progressive multiple sclerosis.
¶Other neurological diseases.
**Other neurological inflammatory diseases.
Figure 1 highly elevated cerebrospinal fluid (csF) free light chains (FLc) κ:λ ratios are detectable in multiple sclerosis (Ms). The concentrations of (a) κ 
and (B) λ FLc and (c) the ratio were determined for csF from clinically isolated syndrome (cIs), relapsing-remitting Ms (RRMs), primary-progressive Ms 
(ppMs), other neurological diseases (OND) and other neurological inflammatory diseases (ONID). (D) Repeat csF samples at the indicated time interval 
were also analysed where available for one cIs (green circle) and two RRMs (red squares). Kruskal-Wallis with Dunn’s post-test; *p<0.05; **p<0.01; 
***p<0.001, all other comparisons non-significant (p>0.05).
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Ig heavy and light chain isotype determination
Antibodies specific for human IgA, IgG1-Fc, IgG2-Fc, IgG3 
hinge, IgG4-Fc and IgM (Southern Biotech, Birmingham, 
Alabama, USA) were coupled to carboxylated xMAP fluorescent 
microspheres using the xMAP Antibody Coupling Kit (Luminex 
Corporation, Austin, Texas, USA) according to the manufac-
turer’s instructions. For CSF analysis, all incubation steps were 
for 30 min at room temperature with agitation followed by two 
washes in phosphate-buffered saline (PBS). CSF samples (50 µL) 
were added to a mixture of antibody-coated microspheres 
(50 µL) and 50 µL assay buffer (PBS 5%, bovine serum albumin, 
5% goat serum), followed by 50 µL of biotin goat anti-human κ 
or λ light chain-specific antibodies (Southern Biotech; 2 µg/mL 
in assay buffer), then streptavidin R-phycoerythrin (Biolegend; 
4 µg/mL). Samples were analysed using a Luminex-200 and 
xMAP software, with final concentrations calculated from stan-
dard curves.
IGKV and IGLV sequencing
RNA isolation and cDNA synthesis from CSF cell pellets were 
performed using the μMACS One-step cDNA Kit (Miltenyi 
Biotec) according to the manufacturer’s instructions. Synthesised 
cDNA was eluted from the column and collected with 50 µL 
cDNA elution buffer. Immunoglobulin Kappa Variable (IGKV) 
and Immunoglobulin Lambda Variable (IGLV) sequencing of 
cDNA were performed by Adaptive Biotechnologies (Seattle, 
Washington, USA) using the immunoSEQ survey level assay.
data analysis
Statistical analyses were performed using GraphPad Prism V.7.0 
(GraphPad Software, California, USA). All data sets were deter-
mined to require non-parametric testing following use of the 
D’Agostino and Pearson normality test and were two tailed.
resuLTs
elevated CsF κ:λ Ig light chain ratios are present in Ms
Ig FLC, in addition to OCB, are present in the CSF of patients 
with MS and are highly sensitive and specific in supporting a 
diagnosis of MS.10 17 18 Here, we confirm these findings in a 
large cohort, demonstrating elevated κFLC, and to a lesser 
extent λFLC, in the majority of patients with CIS, RRMS and 
PPMS (figure 1A, B). The lower λFLC levels led us to examine 
the ratio of CSF κ:λ FLC, recently suggested to be elevated in 
some MS CSF and be prognostic for CIS to CDMS conversion.11 
Within all MS groups, we observed significantly elevated but 
highly variable CSF κ:λ FLC ratios, but not in control groups 
(figure 1C); CIS 18.2; 95% CI 6.8 to 30.3, RRMS 4.4; 95% CI 
2.7 to 11.4, PPMS 12.0; 95% CI 3.6 to 37.1, OND 1.61; 95% CI 
1.4 to 1.9 and ONID 1.7; 95% CI 1.3 to 2.2. Repeated CSF 
analysis in three individuals with RRMS showed a largely stable 
ratio over an interval of up to 418 days (figure 1D). The bias 
towards κFLC was not observed in the serum of these individ-
uals (data not shown).
CsF κ:λ FLC ratios predict Ms disability accumulation
The highly variable CSF κ:λ FLC ratio in all MS groups led us 
to assess whether this ratio might be prognostic for disability 
accumulation. EDSS were determined at a 5-year follow-up time 
point following the diagnostic lumbar puncture. We divided the 
cohort into high (>10) and low (<10) CSF κ:λ FLC ratio groups 
based on approximately equal numbers in each group. There was 
a significantly lower EDSS at follow-up in the group of individ-
uals with a high CSF κ:λ FLC ratio, with the lower ratio group 
accumulating greater disability (figure 2A). There was also a 
significant correlation between CSF κ:λ FLC ratio and EDSS 
at follow-up (r=−0.37; p=0.049). The sensitivity and speci-
ficity of a CSF κ:λ FLC ratio at <9.0 for predicting an EDSS 
Figure 2 cerebrospinal fluid (csF) κ:λ free light chain (FLc) ratio predicts disability accumulation in multiple sclerosis (Ms). (a) expanded disability status 
scale (eDss) at 5-year follow-up (following diagnostic lumbar puncture; where available) for high (>10) and low (<10) csF FLc κ:λ ratio groups (n=15 and 
n=14, respectively); Mann-Whitney test; *p<0.05. The percentage of individuals reaching (B) eDss 3.0, 4.0 or 6.0, (c) annualised relapse rates (aRR), (D) 
the presence of infratentorial lesions, (e) those remaining at clinically isolated syndrome (cIs) (cIs–cIs) or converting to clinically definite Ms (cIs–cDMs) 
and (F) those requiring physician determined first-line or second-line therapy are shown for the high and low csF κ:λ ratio groups. (G) correlation between 
csF neurofilament light chains and immunoglobulin FLc κ:λ ratios; spearman correlation.
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of ≥3.0 at the 5-year follow-up period was 75.0% and 57.1%, 
respectively. Neither kappa nor lambda by themselves were 
significantly associated with disability progression. For EDSS 
3.0, 4.0 and 6.0, there were greater proportions reaching these 
scores during the follow-up period in the lower CSF κ:λ FLC 
ratio group (figure 2B). We also examined several other stan-
dard clinical disease activity-related parameters. Although none 
of these reached statistical significance, likely due to the number 
of individuals where sufficiently detailed clinical data were avail-
able, all were consistent with the CSF κ:λ FLC ratio predicting 
disease severity. There was a small increase in annualised relapse 
rates over the 5-year follow-up period in the low CSF κ:λ FLC 
ratio group (figure 2C; 0.18 vs 0.23), a lower CSF κ:λ FLC 
ratio in those with infratentorial lesions (figure 2D), a higher 
κ:λ FLC ratio at diagnostic lumbar puncture for the group that 
remained CIS at the end of a 5-year follow-up period (figure 2E; 
42.4 vs 21.4) and the group that required neither first-line or 
second-line therapy during the 5-year follow-up period, as 
determined by the treating physician, had a higher CSF κ:λ FLC 
ratio (figure 2F; 26.9 vs 4.8). There was no correlation between 
the CSF κ:λ FLC ratio and the time between disease onset and 
FLC measurement (r=−0.1207; p=0.56). Collectively, these 
data show that the CSF κ:λ FLC ratio at the time of diagnosis is 
predictive of the subsequent MS disease course. Concentrations 
of NFL in CSF have been previously associated with disease 
progression in MS.19 Consistent with this observation, there 
was a negative correlation between CSF NFL and Ig κ:λ FLC 
ratio (figure 2F). However, CSF NFL levels did not significantly 
correlate with disability accumulation (r=0.16; p=0.42) indi-
cating that the CSF κ:λ FLC ratio is a better biomarker in MS.
Altered Ig light chain ratios are intrinsic to CsF plasmablasts
There are several possible explanations for the bias towards κFLC 
in the CSF of patients with MS, unrelated to their antigenic spec-
ificity, including assay-dependent sensitivity for either κ or λ, in 
the FLC and/or intact Ig. We therefore examined the κ and λ light 
chains present in the intact IgG1, IgG2, IgG3, IgG4, IgA and IgM in 
CSF of patients with MS. It was clear that the observed bias towards 
CSF κFLC was recapitulated when examining IgG1κ and IgG1λ, 
with a strong correlation between the IgG1 κ:λ ratio and FLC κ:λ 
ratio (figure 3). There were also significant, but far weaker, correla-
tions with IgG4 and IgM. To formally establish that the CSF FLC 
κ:λ ratio is directly associated with intrathecal antibody-secreting 
cells, we examined CSF B cells and plasmablasts. There were few 
B cells in the CSF of the control cohorts (OND and ONID), which 
increased in MS groups, although not reaching statistical signifi-
cance (figure 4A, Supplementary figure e2). In contrast, there were 
significant increases in both CIS and RRMS plasmablasts, with 
none detected in the OND cohort (figure 4A), consistent with 
previous reports.20 There were significant increases in IgG+ B 
cells in the CSF as compared with blood, suggesting exclusion of 
IgA+ B cells (figure 4B, online Supplementary figure e1). Strikingly, 
CSF plasmablasts were almost entirely IgG+, consistent with the 
high levels of IgG1 detected in the CSF. Peripheral blood B cell 
and plasmablast κ:λ ratios were normal, whereas in some CSF 
samples, there was a clear bias towards κ-expressing plasmablasts 
(figure 4C), with the CSF κ:λ FLC ratio significantly correlating 
with the plasmablast but not the CD19+ CD20+ B cell κ:λ FLC 
ratios (figure 4D). To further validate that the high CSF κ:λ FLC 
ratios were intrinsic to the CSF cells, we sequenced the CDR3 
Ig light chain regions of the CSF cells from three patients with MS 
(figure 4E), with use of cDNA biasing towards plasmablast-de-
rived sequences.21 All samples showed oligoclonal populations as 
determined by both unique clone identification and gene segment 
usage. One showed little bias to IGKV, whereas the other two 
demonstrated a dramatic bias towards IGKV, with very few IGLV 
sequences detected. In summary, the results demonstrate that the 
high CSF κ:λ FLC ratios, which predict disability accumulation, 
are not an epiphenomenon of FLC measurement but result from a 
selective expansion of κ light chain expressing plasmablasts found 
within the CSF of patients with MS.
dIsCussIOn
Although the past two decades have seen major advances in the 
sophistication and availability of diagnostic modalities used in MS 
(particularly MRI), the prognostic heterogeneity of MS makes 
temporal disability prediction extremely difficult for any given 
individual.22 The most recent MRI in multiple sclerosis consensus 
guidelines highlight the prognostic limitations of MRI in the predic-
tion of disability23 and validated prognostic markers are critically 
needed. The presence of CSF OCB at diagnosis doubles the risk 
of further relapse, but does not provide further information on 
the development of disability.24 The detection of IgM OCB may 
be an exception, with positive patients experiencing more relapses, 
a higher requirement for therapy and accumulation of more 
disability.25
In this study, we demonstrated, for the first time, that the ratio 
of κ:λ Ig FLC measured at the time of diagnostic lumbar puncture 
predicts EDSS disability at 5 years postdiagnosis. This is a critical 
advance on previous studies indicating that the ratio of κ:λ FLC in 
Figure 3 correlation between cerebrospinal fluid (csF) free light 
chain (FLc) and intact immunoglobulin κ:λ ratios. correlations are shown 
between csF FLc κ:λ ratio and the κ:λ ratio of csF immunoglobulin (Ig)
G1, IgG2, IgG3, IgG4 and IgM; spearman correlations.
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the CSF might predict the conversion from CIS to CDMS.11 The 
strength of the correlation was not very high (r=−0.37) suggesting 
that additional factors influence the accumulation of disability. 
Although we did not detect a significant difference when exam-
ining conversion from CIS, it was clear that patients with MS 
demonstrating a high CSF κ:λ FLC were more likely to remain 
CIS over time. Voortman et al failed to detect any relationship to 
disability progression, possibly due to a lower frequency of high 
CSF κ:λ FLC ratio individuals in their study and/or the shorter 
follow-up period examined. Our data show that for patients with 
MS demonstrating a low CSF κ:λ light chain ratio at diagnosis, the 
combined profile of greater conversion from CIS, higher relapse 
rates, increased disability progression and greater requirement for 
therapeutic intervention suggest that this immunological feature of 
MS is highly predictive of aggressive disease and poor prognosis, 
although it is worth noting that only disability progression was 
significantly different.
The presence of B cells and their secreted antibody and FLC in 
the CSF and brain tissue is well established.10 17 20 26 27 However, 
little evidence exists for a direct role of secreted antibody in MS 
Figure 4 The bias to κ light chain usage is intrinsic to cerebrospinal fluid (csF) plasmablasts. (a) The frequency of B cells (cD19+ and cD20+) 
and plasmablasts (according to the gating strategy in the online supplementary figure e1) was determined for clinically isolated syndrome (cIs), 
relapsing-remitting multiple sclerosis (RRMs), primary-progressive multiple sclerosis (ppMs), other neurological diseases (OND) and other neurological 
inflammatory diseases (ONID). (B) For csF and matched peripheral blood samples, immunoglobulin (Ig)a, IgG and IgM isotypes were determined on both 
cD19+ cD20+ B cells and plasmablasts. Kruskal-Wallis with Dunn’s post-test; ***p<0.001; **p<0.01; *p<0.05, all other comparisons non-significant 
(p>0.05). The frequency of κ-expressing and λ-expressing total B cells, IgG+ B cells and plasmablasts was determined by flow cytometry (c; representative 
plots for cIs (Ms1) and RRMs (Ms2)) and correlated with the csF free light chain (FLc) κ:λ ratio (D); spearman correlations. (e) The frequency of each 
Immunoglobulin Kappa Variable (IGKV); red and Immunoglobulin Lambda Variable (IGLV); green) gene segments was determined from the cDNa of csF cells 
for Ms3 (ppMs), Ms4 (cIs) and Ms5 (cIs).
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pathogenesis. The success of anti-B cell therapy points towards 
this,28 29 but cannot be distinguished from the role of B cells as 
highly efficient presenters of antigen to T cells. Our data raise an 
intriguing possibility that the spreading of the antibody repertoire, 
starting from the predominant use of κ light chains and leading to 
a mixture of κ and λ, might be involved in disease progression and 
therefore pathogenesis, with remaining questions about the antigen 
specificity of these antibodies. There are many candidate antigens in 
the literature,30–33 and it is possible that some of these account for 
the differential light chain usage. Although most research focuses 
on the role of heavy chains in antigen recognition, accumulation 
of hypermutated sequences in the complementarity-determining 
regions and the codominant role of heavy and light chains in 
antigen binding demonstrate a clear role for light chains.34 35
The availability of a prognostic marker in the CSF at the time 
of diagnosis is of clear utility. There are now many highly effica-
cious therapies for MS, making a rational choice difficult for any 
individual patient, particularly as some are associated with a signifi-
cant adverse event profile. MRI protocols are now well established 
for the diagnosis and therapeutic monitoring of patients with MS. 
The use of CSF κ and λ assay measurements at diagnosis may 
help to identify patients with a poor prognosis, justifying the use 
of highly effective therapies, with potential benefit on long-term 
outcomes. Larger independent studies would be required to vali-
date the findings and determine the ultimate clinical utility of these 
measurements.
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